180 related articles for article (PubMed ID: 25356940)
1. HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
Pennacchia I; Vecchio FM; Carbone A; Arena V
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):31-5. PubMed ID: 25356940
[TBL] [Abstract][Full Text] [Related]
2. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
Kovács A; Stenman G
Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
[TBL] [Abstract][Full Text] [Related]
3. Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH.
Leong AS; Formby M; Haffajee Z; Clarke M; Morey A
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):384-9. PubMed ID: 17122633
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
6. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
7. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
9. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
10. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
13. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
14. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Denoux Y; Fiche M; Jacquemier J; Mathieu MC; Penault-Llorca F; Rigaud C; Roger P; Treilleux I; Vilain MO; Mathoulin-Pélissier S; Le Doussal V
Histopathology; 2003 Apr; 42(4):337-47. PubMed ID: 12653945
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
16. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
[TBL] [Abstract][Full Text] [Related]
17. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice.
Manion E; Hornick JL; Lester SC; Brock JE
Am J Clin Pathol; 2011 Jun; 135(6):845-51. PubMed ID: 21571957
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
19. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
J Clin Pathol; 2011 Jun; 64(6):490-2. PubMed ID: 21415056
[TBL] [Abstract][Full Text] [Related]
20. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
